Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PENINSULA: VIR-2482 for Prevention of Influenza A
NCT05567783Phase 2Terminated
- Sponsor
- Vir Biotechnology
- Start
- Oct 2022
- Primary completion
- May 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of VIR-2482 in Influenza A (IAV), sponsored by Vir Biotechnology. Started Oct 2022; status: terminated.
02
Drugs
VIR-2482
03
Conditions
Influenza A (IAV)
Beyond the preview
Go deeper on NCT05567783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05567783.